Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Lyra Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $77.50 Mil. Lyra Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was $141.53 Mil.
Therefore, Lyra Therapeutics's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.55.
The historical rank and industry rank for Lyra Therapeutics's Equity-to-Asset or its related term are showing as below:
LYRA'
s Equity-to-Asset Range Over the Past 10 Years
Min: -8.24 Med: 0.7 Max: 0.94
Current: 0.55
During the past 6 years, the highest Equity to Asset Ratio of Lyra Therapeutics was 0.94. The lowest was -8.24. And the median was 0.70.
LYRA's Equity-to-Asset is ranked worse than 60.65% of 1558
companies
in the Biotechnology industry
Industry Median: 0.67
vs LYRA: 0.55
Lyra Therapeutics Equity-to-Asset Historical Data
The historical data trend for Lyra Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Lyra Therapeutics's Equity-to-Asset
For the Biotechnology subindustry, Lyra Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lyra Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lyra Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Lyra Therapeutics's Equity-to-Asset falls into.
Lyra Therapeutics Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Lyra Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Lyra Therapeutics Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Lyra Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Lyra Therapeutics (Lyra Therapeutics) Business Description
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LYRA has been successfully added to your 